ORIX vs Nomura
IX and NMR side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IX and NMR compare
ORIX grew revenue faster over the last twelve months (15.9% versus 0.46% for Nomura).
ORIX keeps more of each dollar of sales as profit, with a net margin of 13.4% compared with 7.6% at Nomura.
ORIX scores higher on the StockData Score (6 against 5 for Nomura), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IX | NMR |
|---|---|---|
| Size and price | ||
| Share price | $36.83 | $9.38 |
| Change, 1 year | 51.5% | 32.7% |
| Change, 5 years | 83.8% | 109% |
| Beta (5Y) | 0.73 | 0.96 |
| Employees | 34K | – |
| StockData Score | ||
| Total score | 6 (better) | 5 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 2 (better) |
| Performance score | 3 (better) | 2 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | 15.9% (better) | 0.46% |
| Revenue growth, 5Y average | 7.8% | 24.1% (better) |
| Net income growth (TTM) | 27.2% (better) | 6.3% |
| EPS growth (TTM) | – | 7.2% |
| EPS growth, 5Y average | – | 19.6% |
| Profitability | ||
| Operating margin | 13.7% | – |
| Net margin | 13.4% (better) | 7.6% |
| FCF margin | – | −25.2% |
| Return on equity | 10.4% (better) | 10.1% |
| Return on invested capital | 8.5% | – |
| Financial health | ||
| Debt / equity | 0.13 (better) | 0.47 |
| Net debt / EBITDA | −0.89 | −0.80 |
| Interest coverage | 2.4× | – |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Payout ratio | 38.2% | 49.6% |
| Years of dividend growth | 2 | – |
| Dividend growth, 5Y average | 14.8% | – |
| Ownership | ||
| Held by institutions | 3.3% | 3.0% |
| Held by insiders | 0.29% | 0.12% |
| Insider net buying, 12 months | $3.1K | $3.9K (better) |
Go deeper
- IX stock overview
- IX income statement
- IX valuation and score
- NMR stock overview
- NMR income statement
- NMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.